A
Acumen Pharmaceuticals, Inc. (ABOS)
NMS – Real Time Price. Currency in USD
2.26
-0.29 (-11.37%)
At close: Mar 27, 2026, 4:00 PM EDT
2.26
0.00 (0.00%)
After-hours: Mar 27, 2026, 6:31 PM EDT
Get all premium features to the best stock analysis tool
NMS – Real Time Price. Currency in USD
2.26
-0.29 (-11.37%)
At close: Mar 27, 2026, 4:00 PM EDT
2.26
0.00 (0.00%)
After-hours: Mar 27, 2026, 6:31 PM EDT
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.
| Name | Position |
|---|---|
| Dr. Caleb E. Finch Ph.D. | Co-Founder |
| Dr. Grant A. Krafft Ph.D. | Co-Founder |
| Dr. James Doherty Ph.D. | President & Chief Development Officer |
| Dr. William L. Klein Ph.D. | Co-Founder |
| Mr. Daniel J. O'Connell M.B.A. | CEO & Director |
| Mr. Derek M. Meisner Esq., J.D. | Chief Legal Officer & Corporate Secretary |
| Mr. Matt Zuga | CFO & Chief Business Officer |
| Mr. Russell Barton M.S. |
| Date | Type | Document |
|---|---|---|
| 2026-03-16 | 8-K | abos-20260313.htm |
| 2026-01-12 | 8-K | abos-20260112.htm |
| 2025-11-12 | 8-K | abos-20251112.htm |
| 2025-11-10 | 8-K | abos-20251106.htm |
| 2025-08-12 | 10-Q | abos-20250630.htm |
| 2025-07-15 | 8-K | abos-20250715.htm |
| 2025-06-05 | 8-K | abos-20250604.htm |
| 2025-05-13 | 8-K | abos-20250513.htm |
| 2025-04-23 | DEFA14A | defa14a2025.htm |
| 2025-03-27 | S-8 | acumenpharma-sx82025.htm |
| Chief Operating Officer |
| Ms. Alex Braun M.B.A. | VP & Head of Investor Relations |
| Ms. Kelly Carranza | Senior Vice President of Finance & Accounting and Corporate Controller |